

ABL Diagnostics continues its surveillance of SARS-CoV-2 variants and prepares for any resurgence of COVID-19 outbreaks

WOIPPY, FRANCE, August 21, 2024 /EINPresswire.com/ -- ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories today announced its DeepChek® offer for SARS-CoV-2 Assays & Software, able to identify, to distinguish and to monitor circulating SARS-CoV-2 variants, indicative of COVID-19 infection and related epidemics, has never been stopped since its launch in 2020.

Today, COVID-19 virus continues to evolve and new variants and mutations like KP.1, KP.2, KP.3 and their sub-lineages keep emerging and now account for most infections in the USA as reported by the Centers for Disease Control and Prevention (CDC) surveillance program in August.

ABL Diagnostics enhanced its efforts recently to be able the monitoring of specific SARS-CoV-2 variants of interest and to be prepared for any resurgence of a new COVID-19 epidemics and limits its impacts.

The percentage of people reporting positive tests has reached its highest point since January 2023 with dramatic increase of hospitalizations due to COVID-19 which raises the risk of new epidemics. ABL Diagnostics tightly scrutinizes the evolution of this viral dynamic and keeps updating its panel of DeepChek® SARS-CoV-2 Next Generation Sequencing (“NGS”) assays with latest sets of primers. ABL Diagnostics also keeps updating its DeepChek® SARS-CoV-2 software to classify all known strains within minutes.

“Our R&D team keeps a constant watch on technical and scientific developments, enabling us to provide virology laboratories with up-to-date whole genome kit and software capable of coping with rapid virus evolution.” said Dr. Sofiane Mohamed, Head of R&D at ABL Diagnostics.

“We offer our partners targeted programs with different products including SARS-CoV-2, Influenza, RSV Whole Genome solutions at the best possible conditions, so that together we can face up and differentiate among possible epidemic outbreaks within these respiratory viruses”, added Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics.

ABOUT ABL DIAGNOSTICS

ABL DIAGNOSTICS S.A. (ABLD) is a worldwide leading international company offering innovative and proprietary molecular biology assays and end-to-end solutions intended to be used for molecular detection by Polymerase Chain Reaction (PCR) – UltraGene® and for genotyping through DNA sequencing – DeepChek®.

These molecular biology products cover one of the largest portfolio of microbiology applications, growing fast year after year to stick to the market needs, with a primary focus on HIV (with target-specific assays covering all relevant genes used for drug resistance assessment like reverse transcriptase, protease, integrase and with the disruptive Whole Genome Kit), on SARS-CoV-2, on Tuberculosis (with a multiplex assay targeting genes relevant for first line, second line and new-drugs resistance determination), on viral hepatitis B and C, 16s/18s RNA for taxonomy and microbiome analyses and other viral and bacterial targets.

ABL Diagnostics also develops, manufactures, and markets kits for clinical specimen collection – MediaChek® and digital solutions like Nadis®, an Electronic Medical Record (EMR) system used in France in more than 200 hospitals managing patients infected by HIV or Viral Hepatitis.

ABL Diagnostics, based in Woippy, is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6). For further information, please visit www.abldiagnostics.com.

CONTACTS

ABL Diagnostics
Chalom Sayada
General manager
Tel.: +33 7 83 64 68 50
info@abldiagnostics.com

FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning ABL Diagnostics and its business. Such forward-looking statements are based on assumptions that ABL Diagnostics considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the universal registration document filed with the AMF on July 12, 2022 under number 22-296, available on the web site of ABL Diagnostics (www.abldiagnostics.com) and to the development of economic conditions, financial markets and the markets in which ABL Diagnostics operates. The forward-looking statements

contained in this press release are also subject to risks not yet known to ABL Diagnostics or not currently considered material by ABL Diagnostics. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of ABL Diagnostics to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for ABL Diagnostics shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

Dr Sayada
ABL Diagnostics SA
+33 7 83 64 68 50
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/736758269>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.